Dr. Kassem Faraj and his co-authors at the University of Michigan found 340B was associated with better treatment adherence for more vulnerable prostate cancer patients.
340B Hospitals’ Low-Income Prostate Cancer Patients Had Better Adherence
Although 340B participation did not correlate to the start of costly treatment for men with advanced prostate cancer enrolled in [...]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.